Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
233 hedge funds and large institutions have $260M invested in Sorrento Therapeutics, Inc. in 2022 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 78 increasing their positions, 42 reducing their positions, and 20 closing their positions.
244% more call options, than puts
Call options by funds: $8.55M | Put options by funds: $2.49M
86% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 42
35% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 20
2% more funds holding
Funds holding: 229 → 233 (+4)
16% less capital invested
Capital invested by funds: $309M → $260M (-$48.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$4.15M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.68M |
| 3 |
Rafferty Asset Management
New York
|
+$2.82M |
| 4 |
Goldman Sachs
New York
|
+$2.43M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4.25M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.04M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.87M |
| 4 |
SG Americas Securities
New York
|
-$824K |
| 5 |
Jane Street
New York
|
-$811K |
SRNE Hedge Fund Activity: Q3 2022 in Review
233 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q3 2022, worth a combined $260M — down 16% from $309M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new SRNE positions and 20 closed out — a net gain of 7 holders — while 78 added to existing stakes and 42 trimmed.
The largest buyer was Barclays, adding an estimated $4.15M. The largest seller was Morgan Stanley, cutting an estimated $4.25M.
- 233 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q3 2022, up from 229 in Q2 2022.
- Funds reported $260M of Sorrento Therapeutics, Inc. stock for Q3 2022, down 16% quarter-over-quarter.
- 27 funds opened new Sorrento Therapeutics, Inc. positions in Q3 2022 and 20 closed out, a net change of +7 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q3 2022 was Barclays, an estimated $4.15M added.
- The largest Sorrento Therapeutics, Inc. seller in Q3 2022 was Morgan Stanley, an estimated $4.25M sold.
Based on aggregated 13F filings for Q3 2022.